Shots:

• Aegerion (subsidiary of Novelion Therapeutics) to receive $25M upfront- $5M milestones- and royalties on sales of a product. Recordati to get exclusive commercialization rights for Aegerion’s Juxtapid in Japan
• The focus of the agreement is to develop & commercialize Juxtapid and to strengthen Recordati’s portfolio of rare diseases products in Japan
• Juxtapid (lomitapide) is a microsomal triglyceride transfer protein inhibitor has received approval from Japan’s MHLW for homozygous familial hypercholesterolemia (HoFH)- with sales of $10.8M in 2018- in Japan

Ref: Globe Newswire | Image: Amazon